medigraphic.com

2018, Número 2

<< Anterior Siguiente >>

Rev Clin Esc Med 2018; 8 (2)


El Proteosoma, sus Inhibidores y Toxicidad Cardíaca

Rodriguez PMA, Méndez LMA

Idioma: Español
Referencias bibliográficas: 35
Paginas: 11-21
Archivo PDF: 414.20 Kb.


RESUMEN

El proteosoma es clave para mantenimiento de la homeostasis proteica. Los inhibidores del proteosoma son utilizados de forma rutinaria en un subgrupo de pacientes elegibles con mieloma multiple, sin embargo sus efectos terapéuticos de ven limitados por su toxicidad. Recientemente se ha extendido en entendimiento del Sistema Ubiquitina-Proteosoma en tumores sólidos y enfermedades neurológicas, razón por la cual el conocimiento y entendimiento de los efectos secundarios, en especial la cardiotoxicidad, son fundamentales para su posible expasión clínica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Portbury AL, Willis MS, Patterson C. Tearin’ Up My Heart: Proteolysis in the Cardiac Sarcomere. J Biol Chem. 2011;286(12):9929- 9934. doi:10.1074/jbc.R110.170571.

  2. Sanbe A, Osinska H, Saffitz JE, et al. Desmin-related cardiomyopathy in transgenic mice: A cardiac amyloidosis. Proc Natl Acad Sci United States Am . 2004;101(27):10132-10136. doi:10.1073/pnas.0401900101.

  3. Tsukamoto O, Minamino T, Okada K, et al. Depression of proteasome activities during the progression of cardiac dysfunction in pressure- overloaded heart of mice. Biochem Biophys Res Commun. 2006;340(4):1125-1133. doi:https://doi.org/10.1016/j.bbrc.2005.12.120.

  4. Calise J, Powell SR. The ubiquitin proteasome system and myocardial ischemia. Am J Physiol Heart Circ Physiol. 2013;304(3):H337- 49. doi:10.1152/ajpheart.00604.2012.

  5. Barac YD, Emrich F, Krutzwakd-Josefson E, et al. The ubiquitin-proteasome system: A potential therapeutic target for heart failure. J Hear Lung Transplant. 2017;36(7):708-714. doi:10.1016/j.healun.2017.02.012.

  6. Nobel Prize Foundation. The Nobel Prize in Chemistry 2004. https://www.nobelprize. org/nobel_prizes/chemistry/laureates/2004/. Published 2004. Accessed August 29, 2017.

  7. Collins GA, Goldberg AL. The Logic of the 26S Proteasome. Cell. 2017;169(5):792-806. doi:10.1016/j.cell.2017.04.023.

  8. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4(5):349-360. http://dx.doi.org/10.1038/nrc1361.

  9. Esseltine D-L, Mulligan G. An Historic Perspective of Proteasome Inhibition. Semin Hematol. 2012;49(3):196-206. doi:http://dx.- doi.org/10.1053/j.seminhematol.2012.04.009.

  10. Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science. 2001;294(5545):1307-1313. doi:10.1126/science.1063866.

  11. van Bemmelen MX, Rougier J-S, Gavillet B, et al. Cardiac voltage-gated sodium channel Nav1.5 is regulated by Nedd4-2 mediated ubiquitination. Circ Res. 2004;95(3):284- 291. doi:10.1161/01.RES.0000136816.05109.89.

  12. Laing JG, Beyer EC. The Gap Junction Protein Connexin43 Is Degraded via the Ubiquitin Proteasome Pathway. J Biol Chem . 1995;270(44):26399-26403. doi:10.1074/jbc.270.44.26399.

  13. Glass DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol. 2003;5(2):87-90. http://dx.doi.org/10.1038/ncb0203-87.

  14. Depre C, Wang Q, Yan L, et al. Activation of the Cardiac Proteasome During Pressure Overload Promotes Ventricular Hypertrophy. Circulation. 2006;114(17):1821 LP-1828. http://circ.ahajournals.org/content/114/17/1821.a bstract.

  15. Spencer JA, Eliazer S, Ilaria RL, Richardson JA, Olson EN. Regulation of Microtubule Dynamics and Myogenic Differentiation by Murf, a Striated Muscle Ring-Finger Protein. J Cell Biol. 2000;150(4):771 LP-784. http://jcb.rupress.org/content/150/4/771.abstract.

  16. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci . 2001;98(25):14440-14445. doi:10.1073/pnas.251541198.

  17. Ma S, Wang Y, Chen Y, Cao F. The role of the autophagy in myocardial ischemia/reperfusion injury. Biochim Biophys Acta - Mol Basis Dis. 2015;1852(2):271-276. doi:http://dx.doi.org/10.1016/j.bbadis.2014.05.01 0.

  18. Lavandero S, Chiong M, Rothermel BA, Hill JA. Autophagy in cardiovascular biology. J Clin Invest. 2015;125(1):55-64. doi:10.1172/JCI73943.

  19. Nakai A, Yamaguchi O, Takeda T, et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med. 2007;13(5):619-624. http://dx.- doi.org/10.1038/nm1574.

  20. Yan L, Vatner DE, Kim S-J, et al. Autophagy in chronically ischemic myocardium. Proc Natl Acad Sci United States Am . 2005;102(39):13807-13812. doi:10.1073/pnas.0506843102.

  21. Tannous P, Zhu H, Nemchenko A, et al. Intracellular Protein Aggregation Is a Proximal Trigger of Cardiomyocyte Autophagy. Circulation. 2008;117(24):3070 LP-3078. http://circ.ahajournals. org/content/117/24/3070.abstract.

  22. Galvez AS, Diwan A, Odley AM, et al. Cardiomyocyte Degeneration With Calpain Deficiency Reveals a Critical Role in Protein Homeostasis. Circ Res. 2007;100(7):1071 LP-1078. http://circres.ahajournals.org/content/100/7/1071. abstract.

  23. Orlowski RZ, Kuhn DJ. Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade. Clin Cancer Res. 2008;14(6):1649 LP-1657. http://clincancerres.aacrjournals.org/content/14/6 /1649.abstract.

  24. Vinitsky A, Michaud C, Powers JC, Orlowski M. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry. 1992;31(39):9421-9428.

  25. SHINOHARA K, TOMIOKA M, NAKANO H, TONÉ S, ITO H, KAWASHIMA S. Apoptosis induction resulting from proteasome inhibition. Biochem J. 1996;317(2):385 LP-388. http://www.biochemj.org/content/317/2/385.abstract.

  26. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies. J Clin Oncol. 2002;20(22):4420-4427. doi:10.1200/JCO.2002.01.133.

  27. Orlowski RZ, Baldwin Jr AS. NFĸB as a therapeutic target in cancer. Trends Mol Med. 2017;8(8):385-389. doi:10.1016/S1471- 4914(02)02375-4.

  28. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth & and Prolongs Survival in a Murine Model. Cancer Res. 2002;62(17):4996 LP-5000. http://cancerres. aacrjournals.org/content/62/17/4996.abstract.

  29. Drews O, Taegtmeyer H. Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies. Antioxid Redox Signal. 2014;21(17):2322-2343. doi:10.1089/ars.2013.5823.

  30. Paniagua Soriano G, De Bruin G, Overkleeft HS, Florea BI. Toward understanding induction of oxidative stress and apoptosis by proteasome inhibitors. Antioxid Redox Signal. 2014;21(17):2419-2443. doi:10.1089/ars.2013.5794.

  31. Grandin EW, Ky B, Cornell RF, Carver J, Lenihan DJ. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J Card Fail. 2015;21(2):138-144. doi:10.1016/j.cardfail.2014.11.008.

  32. Koulaouzidis G, Lyon AR. Proteasome Inhibitors as a Potential Cause of Heart Failure. Heart Fail Clin. 2017;13(2):289-295. doi:10.1016/j.hfc.2016.12.001.

  33. Herrmann J, Wohlert C, Saguner AM, et al. Primary proteasome inhibition results in cardiac dysfunction. Eur J Heart Fail. 2013;15(6):614-623. doi:10.1093/eurjhf/hft034.

  34. Hedhli N, Lizano P, Hong C, et al. Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload. Am J Physiol - Hear Circ Physiol. 2008;295(4):H1385 LPH1393. http://ajpheart.physiology.org/content/295/4/H13 85.abstract.

  35. Campbell B, Adams J, Shin YK, Lefer AM. Cardioprotective Effects of a Novel Proteasome Inhibitor Following Ischemia and Reperfusion in the Isolated Perfused Rat Heart. J Mol Cell Cardiol. 2017;31(2):467-476. doi:10.1006/jmcc.1998.0880.




2020     |     www.medigraphic.com